Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Cancers|May 16, 2023
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study GroupBettina Jansko-Gadermeir, Michael Leisch, Franz J Gassner, et al.
Cancers|February 10, 2021
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous BiopsiesTeresa Magnes, Sandro Wagner, Aaron R Thorner, et al.
Journal of Clinical Medicine|June 5, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III TrialGabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, et al.
British Journal of Cancer|October 21, 2016
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patientsKatharina T Prochazka, Thomas Melchardt, Florian Posch, et al.
Wiener Klinische Wochenschrift|September 16, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.
European Journal of Haematology|February 7, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIMFlorian Huemer, Thomas Melchardt, Bettina Jansko, et al.
Scientific Reports|August 14, 2025
C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemiaAlejandra Gonzalez Martinez, Franz Josef Gassner, Dominik Baumgartner, et al.
Journal of Clinical Pathology|December 9, 2015
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphomaKatharina T Troppan, Thomas Melchardt, Kerstin Wenzl, et al.
European Journal of Haematology|February 14, 2015
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patientsKatharina T Troppan, Thomas Melchardt, Alexander Deutsch, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 13, 2021
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancerKonstantin Schlick, Steiner Markus, Florian Huemer, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Cancers|May 16, 2023
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study GroupBettina Jansko-Gadermeir, Michael Leisch, Franz J Gassner, et al.
Cancers|February 10, 2021
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous BiopsiesTeresa Magnes, Sandro Wagner, Aaron R Thorner, et al.
Journal of Clinical Medicine|June 5, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III TrialGabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, et al.
British Journal of Cancer|October 21, 2016
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patientsKatharina T Prochazka, Thomas Melchardt, Florian Posch, et al.
Wiener Klinische Wochenschrift|September 16, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.
European Journal of Haematology|February 7, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIMFlorian Huemer, Thomas Melchardt, Bettina Jansko, et al.
Scientific Reports|August 14, 2025
C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemiaAlejandra Gonzalez Martinez, Franz Josef Gassner, Dominik Baumgartner, et al.
Journal of Clinical Pathology|December 9, 2015
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphomaKatharina T Troppan, Thomas Melchardt, Kerstin Wenzl, et al.
European Journal of Haematology|February 14, 2015
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patientsKatharina T Troppan, Thomas Melchardt, Alexander Deutsch, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 13, 2021
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancerKonstantin Schlick, Steiner Markus, Florian Huemer, et al.
Pageof 11